Literature DB >> 8552541

Bacterial meningitis after MMR immunisation.

F A Riordan1, J A Sills, A P Thomson, C A Hart.   

Abstract

Two children developed bacterial meningitis within five days of measles-mumps-rubella (MMR) immunisation. Diagnosis was delayed because symptoms were attributed to the vaccine, although both had a raised C-reactive protein. Fever or rash within five days of MMR vaccination are unlikely to be due to the vaccine and a raised C-reactive protein suggests bacterial infection.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8552541      PMCID： PMC2398287          DOI： 10.1136/pgmj.71.842.745

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  6 in total

1.  Features and outcome in meningococcal disease presenting with maculopapular rash.

Authors:  O Marzouk; A P Thomson; J A Sills; C A Hart; F Harris
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

2.  Apparent decreased risk of invasive bacterial disease after heterologous childhood immunization.

Authors:  S B Black; J D Cherry; H R Shinefield; B Fireman; P Christenson; D Lampert
Journal:  Am J Dis Child       Date:  1991-07

3.  Neurologic disorders following live measles-virus vaccination.

Authors:  P J Landrigan; J J Witte
Journal:  JAMA       Date:  1973-03-26       Impact factor: 56.272

4.  Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins.

Authors:  H Peltola; O P Heinonen
Journal:  Lancet       Date:  1986-04-26       Impact factor: 79.321

5.  Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children.

Authors:  E Miller; M Goldacre; S Pugh; A Colville; P Farrington; A Flower; J Nash; L MacFarlane; R Tettmar
Journal:  Lancet       Date:  1993-04-17       Impact factor: 79.321

6.  Variation in serum C-reactive protein across the clinical spectrum of meningococcal disease.

Authors:  O Marzouk; K Bestwick; A P Thomson; J A Sills; C A Hart
Journal:  Acta Paediatr       Date:  1993-09       Impact factor: 2.299
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.